Preclinical proof-of-concept data show the therapeutic potential of OTL-104 for NOD2 Crohn’s disease, a severe and treatment-refractory form of the disease In vivo data demonstrate the development of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback